Aurobindo Pharma Transfers Domestic Branded Generic Formulations Business to Subsidiary Auropharm Limited
Aurobindo Pharma Ltd announced that its Board of Directors approved the transfer of its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary of the Company. This transaction, structured as a business transfer agreement on a going concern basis, is part of Aurobindo Pharma's strategy to streamline and accelerate its domestic operations for faster growth.The Business Transfer Agreement (BTA) for the transfer of the domestic branded generic pharmaceutical formulations products business was executed on April 6, 2026.
Key financial details regarding the unit being transferred are as follows:
| Metric | Amount | Percentage of Consolidated Value |
|---|---|---|
| Turnover Contributed (Last Financial Year) | Rs. 1,753.40 Million | 0.55% of consolidated turnover |
| Net Worth Contributed (Last Financial Year) | Rs. 1,481.40 Million | 0.45% of consolidated net worth |
The lump sum consideration for the transfer of the business is set at INR 143.21 Crores (Rs. One Hundred Forty- Three Crores and Twenty-One Lakhs only), subject to adjustments specified in the BTA.
Transaction Timeline and Structure
The completion of the sale is estimated to occur within 90 to 120 days from the date of the BTA, pending the satisfaction of customary conditions precedent under the BTA. Upon completion, the economic benefits of the business are expected to transfer to Auropharm Limited starting from April 1, 2026.The transfer is being conducted between the holding company and its wholly owned subsidiary, making the two related parties. The Company noted that such a transaction between a holding company and its wholly owned subsidiary has no impact on a consolidated basis.
Business Scope
Aurobindo Pharma Limited is involved in formulating, manufacturing, distribution, marketing, and sales of a wide range of pharmaceuticals, APIs, and injectables, alongside research and development in various countries with a multi-product portfolio. In contrast, Auropharm Limited focuses on the trade of branded generic formulations and pharmaceuticals products in India.The rationale for the slump sale is stated as aligning with the Group's objective to consolidate the domestic pharmaceuticals business under the wholly owned subsidiary. This consolidation effort is intended to assist the Group in expanding its domestic pharmaceuticals business by adopting a more operationally efficient and focused approach.
Details related to the revenue of the standalone entities for the year ended March 31, 2025, are:
| Entity | Standalone Revenue (Year Ended March 31, 2025) |
|---|---|
| Aurobindo Pharma Limited (Standalone) | Rs. 1,09,333 Million |
| Domestic Branded Generic Formulations Business (Standalone) | Rs. 1,753.40 Million |
| Auropharm Limited (Standalone) | Nil |
The Company confirmed there will be no change in the shareholding pattern. The transaction is classified as outside the Scheme of Arrangement and is deemed a slump sale, which means it does not constitute the sale of the whole or substantially the whole of the undertaking of the Company under Section 180(1)(a) of the Companies Act, 2013.
AUROPHARMA Stock Price Movement
Aurobindo Pharma Limited shares dropped by 0.45% to ₹1336 on April 2nd, having traded between ₹1266.1 and ₹1338.9. The stock remains near its 52-week high level and saw high activity, with a total traded volume of 1,870,240.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.